Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

NICE backs first ‘ultra-orphan’ drug Soliris

NICE backs first ‘ultra-orphan’ drug Soliris Alexion's Soliris has become the first drug to pass through a new UK assessment to determine the cost-effectiveness of medicines for very rare conditions. ... These concerns have now been somewhat overcome, although cost still remains an issue and NICE

Assessing drugs for ultra-rare conditions in the UK

Assessing drugs for ultra-rare conditions in the UK Along the way Soliris underwent review by the now-defunct Advisory Group for National Specialised Services (AGNSS). ... Nevertheless, if it needed convincing about Soliris' cost, NICE was impressed with the drug's benefits.

NICE set to back Alexion's costly 'ultra-orphan' drug

NICE set to back Alexion's costly 'ultra-orphan' drug on high cost drugs - and Soliris' price has previously been a problem for NICE. ... Alexion estimated Soliris produced 25.22 additional QALYs per patient compared with standard care.

Alexion convinces NICE of Soliris' value

Alexion convinces NICE of Soliris' value Alexion's high cost rare disease drug Soliris has been recommended by NICE for use in England under its new approach to highly specialised technologies. ... Soliris (eculizumab) is licensed to treat atypical hemolyic uremic syndrome (aHUS) drug, a

NICE and ‘ultra orphans’

NICE and ‘ultra orphans’ NICE expects to issue its guidance on Soliris by July 2014 and in the meantime NHS England will continue to fund the drug's use for new and existing aHUS patients. ... Soliris remains the only drug so far to be put through NICE's highly specialised

[ Previous 5 results ] 3 4 5 6 7 8 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...